Drugs /

bi 891065

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for bi 891065

Bi 891065 has been investigated in 3 clinical trials, of which 2 are open and 1 is closed. Of the trials investigating bi 891065, 2 are phase 1 (1 open) and 1 is phase 2 (1 open).

Microsatellite Stable (MSS) is the most frequent biomarker inclusion criterion for bi 891065 clinical trials.

Malignant solid tumor, colorectal carcinoma, and adenocarcinoma of the gastroesophageal junction are the most common diseases being investigated in bi 891065 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Bi 891065
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Bi 891065
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating bi 891065 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
BIRC2, BIRC3, BIRC5, BIRC7, XIAP

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.